Phase III Trial of Anaplastic Glioma Without 1p/19q LOH
Status:
Active, not recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving radiation therapy
together with temozolomide may kill more tumor cells. It is not yet known whether giving
temozolomide during and/or after radiation therapy is more effective than radiation therapy
alone in treating anaplastic glioma.
PURPOSE: This randomized phase III trial is studying giving temozolomide during and/or after
radiation therapy to see how well it works compared to radiation therapy alone in treating
patients with anaplastic glioma.
Phase:
Phase 3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators:
Cooperative Trials Group for Neuro-Oncology Medical Research Council Merck Sharp & Dohme Corp. NCIC Clinical Trials Group Radiation Therapy Oncology Group